MCL1 and hepatocellular carcinoma: To date, except for MCL1 which has been proven by us and other literature studying hepatocellular carcinoma (Gao et al., 2018), among the validated miR-26a targets, HMGA1 (Liu et al., 2018), PTEN (Liu et al., 2012), EZH2 (Lu et al., 2011), MITF (Ji et al., 2015), DNMT3B (Lai et al., 2019), TGF-beta (Tripathi et al., 2019), and Ezh2 (Gollner et al., 2017) have been demonstrated to regulate chemoresistance.